Extrapyramidal Symptoms: Incidence, Causative Medications, and Management
The available evidence does not provide specific incidence data for extrapyramidal symptoms (EPS) in the general population or population-specific data for Indian and South Asian countries; however, among patients receiving antipsychotics, EPS occurs in approximately 31-37% of cases, with Indians demonstrating exceptionally high susceptibility (96% incidence) requiring routine prophylactic anticholinergic therapy.
Incidence Data
General Population on Antipsychotics
The pooled prevalence of antipsychotic-induced EPS is 31-37% overall 1. Breaking this down by specific EPS types:
- Parkinsonism: 20% (1 in 5 patients) 1
- Akathisia: 11% (more than 1 in 10 patients) 1
- Tardive Dyskinesia: 7% 1
- Dystonia: 5% 2
Indian and South Asian Populations
Indians show dramatically higher EPS susceptibility compared to other populations. In a prospective study of 71 Indian patients started on conventional antipsychotics, 96% developed EPS while receiving 2-13 mg/day haloperidol equivalents 3. The timeline was rapid:
- 70% developed EPS by day 5
- 90% by day 10
Most common symptoms in Indians were tremor (49%), cogwheel rigidity (40%), and acute dystonic reactions (34%) 3. This exceptionally high incidence justifies the routine Indian clinical practice of prophylactic anticholinergic co-prescription with antipsychotics 3.
Pediatric Populations
Children and adolescents face higher risk than adults for EPS 4. In pediatric populations, antipsychotics carry a 2.24-fold increased risk of EPS compared to placebo (Number Needed to Harm = 7) 5. Up to 50% of youth receiving neuroleptics may experience tardive or withdrawal dyskinesia 4.
Medications Causing EPS and Their Incidence Rates
| Medication Class/Agent | EPS Incidence | Specific Risk Profile |
|---|---|---|
| TYPICAL ANTIPSYCHOTICS | ||
| Depot typical agents | 32.8% overall EPS [6] 11.1% TD [6] |
Highest risk category; TD develops in 50% of elderly after 2 years continuous use [7] |
| Haloperidol | High EPS risk [4] | High-potency agent with greatest dopamine blockade; anticipated EPS [7] |
| Fluphenazine, Thiothixene | High EPS risk [7] | Similar profile to haloperidol |
| Chlorpromazine, Thioridazine | Lower EPS, higher anticholinergic effects [4] | Low-potency agents; more sedation, less EPS |
| ATYPICAL ANTIPSYCHOTICS | ||
| Risperidone | 2.84-fold increased EPS risk vs olanzapine [6] EPS at ≥2 mg/day [7] |
Significant D2 antagonism; dose-dependent EPS |
| Ziprasidone | 3.59-fold increased EPS risk vs placebo [5] | Highest risk among atypicals in pediatric studies |
| Aripiprazole | 2.07-fold increased EPS risk vs placebo [5] | Partial D2 agonist; moderate EPS risk |
| Olanzapine | 7.7% overall EPS [6] 2.8% TD [6] |
Lowest EPS risk among studied agents; reference standard |
| Quetiapine | Low EPS risk [7] | More sedating; minimal EPS |
| Clozapine | Minimal EPS risk [4] | Theoretically lowest EPS; 3% seizure risk, 1% agranulocytosis risk |
| ANTIDEPRESSANTS | ||
| Paroxetine | 8.6-fold increased EPS risk vs citalopram [8] | Highest risk SSRI |
| Imipramine | 8.3-fold increased risk [8] 28.9% incidence [8] |
Highest risk among all studied agents |
| Fluoxetine | 8.2-fold increased risk vs citalopram [8] | High-risk SSRI |
| Amitriptyline | 9.8% incidence [8] | Lowest among tricyclics studied |
| Citalopram | Reference (lowest risk) [8] | Preferred SSRI for EPS avoidance |
Management by EPS Type
| EPS Type | Clinical Features | First-Line Management | Alternative/Adjunct Treatments | Key Considerations |
|---|---|---|---|---|
| ACUTE DYSTONIA | Sudden spastic muscle contractions Neck, eyes (oculogyric crisis), torso Onset: 3-5 days after initiation [4,9] |
Anticholinergics: • Benztropine • Diphenhydramine OR Benzodiazepines [4,9] |
Antihistamines [4] | • Life-threatening if laryngospasm • Risk factors: young age, male gender, high-potency agents [4] • Usually responds well to treatment [4] |
| PARKINSONISM | Bradykinesia, tremors, rigidity Onset: Within 3 months [9] |
1. Lower antipsychotic dose 2. Anticholinergics 3. Amantadine (mild dopaminergic) [4,9] |
Switch to low-potency or atypical antipsychotic [9] | • Difficult to differentiate from negative symptoms or catatonia [4] • Avoid benztropine/trihexyphenidyl in elderly [7] |
| AKATHISIA | Severe restlessness, pacing, agitation Onset: Days to weeks [9] |
1. Lower antipsychotic dose (if feasible) [4,9] 2. Lipophilic β-blockers: • Propranolol (most effective) • Metoprolol [9] |
• Benzodiazepines [4,9] • Anticholinergics (less consistent) [4] |
• Often misinterpreted as psychotic agitation [4] • Common cause of noncompliance [4] • Difficult to treat [4] |
| TARDIVE DYSKINESIA | Involuntary choreic/athetoid movements Orofacial region primarily Onset: Long-term use [4] |
1. Discontinue or switch antipsychotic (if clinically safe) [4] 2. Switch to atypical antipsychotic [4] |
No specific treatment beyond discontinuation [4] | • May persist after discontinuation [4] • Monitor with AIMS every 3-6 months [4] • Continue current dose only if full remission and relapse risk high [4] |
| TARDIVE DYSTONIA | Slow movements with spasms along body axis Facial spasms |
Same as tardive dyskinesia management [4] | None established | • Often associated with TD [4] • Can be quite disabling [4] |
Prophylaxis Strategies
Prophylactic anticholinergic agents should be considered in high-risk patients 4:
- Young age (especially children/adolescents)
- Male gender
- History of dystonic reactions
- High-potency antipsychotic use
- Indian/South Asian ethnicity 3
- Compliance concerns (paranoid patients)
Re-evaluate prophylaxis need after acute phase or dose reduction, as many patients no longer require it during long-term therapy 4.
Risk Factors for EPS Development
Factors increasing EPS risk:
- Age: Younger patients at higher risk for acute EPS 4; older age increases TD risk 6
- Gender: Female sex increases risk (β=0.0136, p=0.023) 5; male gender increases dystonia risk 4
- Smoking: 1.7-fold increased risk 8
- Tremor history: 7.4-fold increased risk 8
- Prior antipsychotic use: 3.9-fold increased risk 8
- High baseline clinical severity: Significantly higher EPS risk 6
- Presence of baseline EPS: Higher TD risk 6
- Gynecomastia: Associated with TD development 6
Protective factor:
- Longer treatment duration: Associated with reduced EPS risk (β=-0.0349, p=0.002) 5, likely due to dose adjustments and tolerance
Critical Clinical Pitfalls
Underdetection: Only 49% of EPS detected by routine clinical care; 19% volunteered by patients; 7% reported by relatives 3. Directly ask and systematically examine for EPS at every visit.
Misinterpretation: Akathisia frequently misdiagnosed as psychotic agitation or anxiety, leading to inappropriate dose increases 4.
Anticholinergic avoidance in elderly: Benztropine and trihexyphenidyl should be avoided in elderly patients with typical antipsychotics 7.
Monitoring frequency: Baseline abnormal movement assessment mandatory; reassess every 3-6 months minimum once on antipsychotics 4.
Indian population management: The 96% EPS incidence in Indians necessitates routine prophylactic anticholinergic co-prescription, contrary to WHO recommendations for other populations 3.